Opioid-conditioned reinforcement is thought to exacerbate opioid abuse and dependence. Sex/gender can influence opioid abuse behaviors, but the effects of sex/gender on opioid-conditioned reinforcement, specifically, are unclear. In this study, we compared new-response acquisition with opioid-conditioned reinforcement in male and female rats. First, separate groups received response-independent remifentanil injections (0.0-32.0 μg/kg, intravenous) and presentations of a light-noise stimulus. In the experimental groups, injections and stimulus presentations always cooccurred [paired Pavlovian conditioning (PAV)]; in the control groups, the two occurred independently of each other (random PAV). Next, in the instrumental acquisition (ACQ) sessions, two novel nose-poke manipulanda were introduced. All animals (regardless of sex, dose, and PAV type) could respond in the active nose-poke, which produced the stimulus alone, or in the inactive nose-poke. Both males and females dose-dependently acquired nosepoke responding (active > inactive) after paired PAV, but not after random PAV. Therefore, the stimulus was a conditioned reinforcer. We identified three sex differences. First, only females acquired responding after paired PAV with 32.0 μg/ kg remifentanil. Second, using a progressive ratio schedule for ACQ, both sexes acquired responding, but females made significantly more active responses. Third, when a single session of PAV was conducted, only males acquired responding. Thus, rats' sex interacts with pharmacological and environmental factors to determine opioid-conditioned reinforcement.
Introduction
Opioid-associated environmental stimuli (i.e. cues) can significantly exacerbate opioid abuse behaviors. Cue presentation enhances ongoing opioid self-administration responding in laboratory animals (e.g. Goldberg and Tang, 1977; Alderson et al., 2000) , and exposure to cues and cue-induced craving have been associated both retrospectively and prospectively with relapse in human opioid abusers (Heather et al., 1991; Unnithan et al., 1992; Lubman et al., 2009; Fatseas et al., 2011; Garland and Howard, 2014) . Attenuating cue effects is an important goal in developing refined treatments for drug abuse and dependence (Taylor et al., 2009; Milton and Everitt, 2010; Myers and Carlezon, 2010; Peck and Ranaldi, 2014) . There are currently Food and Drug Administration approved opioid antagonist and agonist medications available to block or substitute, respectively, for the effects of abused opioids themselves (Bart, 2012) . However, opioid cues can still produce significant motivational effects in patients receiving these medications (Hyman et al., 2007; Lubman et al., 2009; Fatseas et al., 2011) . Additional work is needed specifically to target opioid cue effects and, hence, it is important to clarify the mechanisms by which opioid cues control behavior.
Among Pavlovian drug-conditioned effects (reviewed by Milton and Everitt, 2010) , conditioned reinforcement may be particularly robust or 'insidious' (Robinson et al., 2014 ; see also Di Ciano and Everitt, 2004; Taylor et al., 2009) . Drug-conditioned reinforcement can maintain operant responding for extended periods when the drug is unavailable, and drug-conditioned reinforcers can be used to train novel responses that were not previously reinforced by the drug itself (e.g. Di Ciano and Everitt, 2004; Palmatier et al., 2007; Bertz and Woods, 2013; Bertz et al., 2015) . More generally, conditioned reinforcers can be unaffected by manipulations targeting the primary reinforcer that initially established them (Parkinson et al., 2005; Burke et al., 2007) . Rather, conditioned reinforcement may help maintain behavior in opposition to primary reinforcement contingencies (Pears et al., 2003) . These observations indicate that drug-conditioned reinforcement can enhance both the persistence and the diversity of drug-related behavior in a manner that resists efforts to block or devalue the primary drug reinforcer.
It is, however, also important to recognize the significant sex/gender differences in opioid abuse behaviors that have been reported both preclinically and clinically. Studies in rats have shown that females acquire opioid self-administration more readily than males (Lynch and Carroll, 1999; Carroll et al., 2002) and have enhanced responding once selfadministration is established (Alexander et al., 1978; Klein et al., 1997; Carroll et al., 2001; Cicero et al., 2003) . Patterns are more complicated among human drug users, but work with opioid abusers from several different countries has found that, broadly, women experience more severe clinical courses than men: women transition more quickly from initial opioid use to regular use and/or to treatment intake (i.e. 'telescoping') while experiencing more adverse events/ effects across a wider range of life domains Hser et al., 1987; Hernandez-Avila et al., 2004; Chiang et al., 2007; Kelly et al., 2009; Hölscher et al., 2010; Shand et al., 2011) .
The specific contributions of opioid-associated stimuli to these sex/gender differences are presently unclear. For example, heroin-abusing women have reported greater craving than heroin-abusing men when exposed to personalized descriptions of heroin use situations (Yu et al., 2007) . This effect may indicate sex/gender differences in the motivational effects of drug cues per se, but several other sex/gender-dependent factors, such as participants' willingness to report emotional states in a laboratory setting, may also significantly influence results of this type (Robbins et al., 1999) . Among rats, females showed greater resistance to extinction of oral opioid self-administration when responding continued to produce the stimuli previously associated with drug delivery without the drug itself (Klein et al., 1997) . This difference is consistent with enhanced conditioned reinforcement among females. However, the same response produced both the drug and the stimuli in this case and, thus, the rats' behavior may have depended entirely on the primary reinforcing effects of the drug, with the stimuli having no (conditioned) reinforcing effects of their own (Mackintosh, 1974; Williams, 1994) . Female rats have also shown enhanced opioid-conditioned place preferences (Cicero et al., 2000; Karami and Zarrindast, 2008) , but these differences could, likewise, arise from several different cue-based and/or drug-based behavioral mechanisms (Bardo and Bevins, 2000; Huston et al., 2013) .
To provide a valid measure of sex differences in the conditioned reinforcing effects, in particular, of an opioidassociated stimulus, the present study tested male and female rats for new-response acquisition. To establish a new response with drug-conditioned reinforcement (e.g. Bertz and Woods, 2013) , animals are first given responseindependent drug injections and presentations of exteroceptive stimulus such that the two events either are or are not consistently paired. Thereafter, the animals are given access to novel instrumental responses that either do or do not produce the stimulus alone (i.e. without drug). If the stimulus is a conditioned reinforcer, the animals should significantly prefer the response that produces the stimulus (vs. the response that does not) only after the stimulus was paired with a drug. These procedures provide a stringent test for conditioned reinforcement (Mackintosh, 1974; Williams, 1994) : the response that produces the stimulus does not and did not produce the drug, controlling for primary reinforcing effects, and it can be clearly shown that responding depends on (i) the Pavlovian contingency between the stimulus and the drug and (ii) the instrumental contingency between a particular response and the delivery of the stimulus. Using these strict criteria, the conditioned reinforcing effects of stimuli paired with several classes of abused drugs have been established in male rats (Di Ciano and Everitt, 2004; Palmatier et al., 2007; Bertz and Woods, 2013) . However, previous studies have not, to our knowledge, directly compared the acquisition of responding with drug-conditioned reinforcement in male and female rats.
Three experiments were conducted using the potent, shortacting opioid agonist, remifentanil. Experiment 1 characterized the effect of remifentanil dose on the conditioned reinforcing effects of a remifentanil-paired stimulus in male and female rats. Having found effective doses of remifentanil for both males and females in Experiment 1, Experiment 2 assessed the relative reinforcing efficacy of the stimulus under a progressive ratio (PR) schedule of reinforcement. Finally, Experiment 3 used a reduced number of drug-stimulus pairings to compare the speed with which the stimulus can be established as a conditioned reinforcer in males and females.
Methods

Subjects
Male and female Sprague-Dawley rats (Harlan Laboratories, Indianapolis, Indiana, USA) aged at least 65 days served as subjects in all experiments. During the experiments, males weighed (mean SEM) 353 2 g, whereas females weighed 256 1 g. Each experimental group contained 10 or 12 animals. The animals were housed in a climate-controlled facility under a 12 h light-dark cycle (lights on at 07:00 h) and were allowed to acclimate to the facility for at least 1 week before beginning the experiments. Experimental sessions were conducted on 5-7 days/week during the light phase of the cycle. The animals were housed in same-sex groups of three per cage before the catheterization surgery (described below) and individually thereafter to protect their implants. All animals had unrestricted access to standard pellet chow and laboratory tap water in the homecage throughout. All studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Research CoLS, National Research Council, 2011) , and all experimental procedures were approved by the University of Michigan Committee on the Use and Care of Animals.
Surgery
After acclimating to the facility, the animals were catheterized for intravenous drug administration. The catheters were custom made from polyurethane tubing (MRE-040 or MRE-033; Braintree Scientific, Braintree, Massachusetts, USA) and Tygon tubing (S-54-HL; Norton Performance Plastics, Akron, Ohio, USA). Surgery was performed under ketamine/xylazine (90 : 10 mg/kg, intraperitoneally) anesthesia. The catheter was inserted into the left femoral vein and routed subcutaneously to the scapulae, where it was secured to a fabric mesh backplate (DC95BS; Instech Laboratories, Plymouth Meeting, Pennsylvania, USA or 313-000BM; Plastics One, Roanoke, Virginia, USA) and attached to 22 G stainless steel tubing for externalization. Carprofen (5.0 mg/kg, subcutaneously) was administered for analgesia on the day of and the day after surgery. All animals were allowed to recover for at least 5 days after surgery before the start of experimentation. The catheters were flushed daily with 0.25 ml of heparinized saline (50 U/ml) to ensure patency.
Apparatus
Experimental sessions were conducted in two standard operant-conditioning chambers controlled by Med-PC IV software (Med Associates, St. Albans, Vermont, USA) as described in detail previously (Bertz and Woods, 2013) . Each chamber was contained inside a light-attenuating and sound-attenuating cubicle and was located in a separate room of the laboratory. The right wall of each chamber contained a white incandescent house light (ENV-215M; Med Associates) and a speaker for a tone generator (ENV-224AM and ENV-230; Med Associates). Two nosepoke manipulanda containing LED stimulus lights (ENV-114BM, Med Associates) could also be inserted into the right wall. When the nose-pokes were removed from the chamber, they were replaced by blank aluminum panels.
Motorized syringe drivers (PHM-107; Med Associates) were located outside of the light-attenuating and soundattenuating cubicles to deliver intravenous drug injections. The syringes were attached to Tygon tubing (S-54-HL; Norton Performance Plastics), leading to a counterweighted fluid swivel (375/22PS; Instech Laboratories) and spring tether.
Behavioral procedures
The behavioral testing procedures used were based on a previous study on remifentanil-conditioned reinforcement in male rats (Bertz and Woods, 2013) . Within each experiment, the control animals were tested after the experimental animals, whereas the other experimental conditions (remifentanil doses, male vs. female rats) were tested in a nonsystematic order.
Pavlovian conditioning
After recovery from surgery, the animals underwent either 'paired' or 'random' Pavlovian conditioning (PAV) sessions. During the PAV sessions, the nose-poke manipulanda were removed from the experimental chambers, and all animals received response-independent intravenous injections of remifentanil and presentations of a light-noise compound stimulus. The light-noise stimulus consisted of house-light illumination and white noise (80 5 dB measured at the chamber's center). Injections and stimulus presentations lasted ∼ 2.0 s, varying depending on the weight of the individual animal (male mean: 2.0 s, male range: 1.5-2.4 s; female mean: 2.2 s, female range: 1.8-2.6 s). In the paired PAV groups, a single variable time (VT) 3-min schedule (range: 0.0-6.0 min) controlled both remifentanil injection and stimulus presentation, and injections and stimulus presentations always co-occurred. In random PAV control groups, remifentanil injection and stimulus presentation were controlled by independent VT 3-min schedules and were not explicitly unpaired. All PAV sessions lasted until 20 injections and 20 stimulus presentations occurred -that is, ∼ 60 min.
In Experiment 1, the following unit doses (μg/kg) of remifentanil were administered to separate groups of male or female rats in paired PAV: 0.0, 1.0, 3.2, 10.0, or 32.0. These doses were chosen from previous studies on remifentanil selfadministration in rats (Panlilio and Schindler, 2000; Panlilio et al., 2003) . On the basis of their effects in paired PAV, the following unit doses (μg/kg) of remifentanil were administered to separate groups of control male or female rats in random PAV: 3.2, 10.0, or 32.0. On the basis of the results of Experiment 1, 10.0 μg/kg remifentanil was administered to all groups in Experiments 2 and 3. In all cases, remifentanil dose was set by changing the concentration of the remifentanil solution, not by altering the infusion duration.
In Experiments 1 and 2, PAV was conducted for five consecutive sessions (100 total drug/stimulus pairings, 'extensive pairing'). In Experiment 3, PAV was conducted for one session (20 total drug/stimulus pairings, 'limited pairing').
Instrumental acquisition
After PAV, all animals (regardless of sex, remifentanil dose, and PAV type) were tested in a series of instrumental acquisition (ACQ) sessions. During ACQ, the two nose-pokes were present in the experimental chambers. The start of each ACQ session was indicated by the illumination of the stimulus lights inside both nosepokes, and both nose-pokes remained illuminated for the duration of the session. The side of the active nosepoke (right vs. left) was counterbalanced between subjects within each group. Remifentanil was never administered during ACQ. Responses in the inactive nosepoke were recorded but had no scheduled consequences. Responses in the active nose-poke produced the lightnose stimulus alone, as detailed below.
In all experiments, seven ACQ sessions (ACQ1-7) were conducted, but the schedule of reinforcement and session duration varied among experiments. In Experiments 1 and 3, active responses were reinforced under a modified random ratio (RR) 2 schedule: the first active response in each session produced the stimulus with a probability of 1.0, whereas each Opioid-conditioned reinforcement in the rat Bertz et al. 139 subsequent active response in the session produced the stimulus with a probability of 0.5. RR2 ACQ sessions lasted 60 min. In Experiment 2, ACQ1 was conducted under the RR2 schedule as described above. Thereafter, in ACQ2-7, active responses were reinforced under a PR schedule: ratio requirements increased within the session (1, 2, 4, 6, 9, 12, 15, 20, 25, 32, etc.) according to the equation of Richardson and Roberts (1996) : ratio value = [5e (reinforcer number × 0.2) ] − 5. The PR sessions lasted for 240 min or until a ratio requirement was not completed for 45 min, whichever occurred first.
Drugs
Remifentanil (Ultiva brand; GlaxoSmithKline, Uxbridge Middlesex, UK or Mylan Institutional, Rockford, Illinois, USA) was obtained from the hospital pharmacy of the University of Michigan Health System and dissolved in sterile physiological saline. All injections were administered at a volume of 0.1 ml/kg.
Data analysis
In Experiments 1 and 3, preference for the active response was calculated (active responses − inactive responses) for each animal in each ACQ session. As raw data, considering all conditions, responding ranged as follows: male active, 0-81; male inactive, 0-56; female active, 0-143; female inactive, 0-61. Animals were considered to have successfully acquired responding for the stimulus if they made significantly more active responses than inactive responses, which, in this case, manifested as preference scores significantly greater than zero. Preference scores were analyzed separately for paired PAV groups and random PAV groups. In Experiment 1, preference scores were analyzed using a three-way analysis of variance (ANOVA), with the within-subjects factor of session (ACQ1-7) and the between-subjects factors of sex (male, female) and remifentanil dose (0.0-32.0 μg/kg). In Experiment 3, because only one dose of remifentanil was tested, and because only males acquired responding, preference scores were analyzed using a two-way ANOVA, with the within-subjects factor of session and the between-subjects factor of sex (after paired PAV), or using a one-way ANOVA, with the within-subjects factor of session (after random PAV). In both experiments, following nonsignificant effects involving session, mean preference scores were compared pairwise using post-hoc Bonferroni-corrected t-tests. To assess significant effects involving dose, one-sample t-tests were used to compare preference scores with zero. To assess sex differences, independent-samples t-tests were used to compare males with females. Corrected P-values have been reported in all cases. Finally, in Experiment 3, the number of 'chance pairings' during random PAV was calculated as the number of times remifentanil injection and stimulus presentation co-occurred given the independent operation of the two VT schedules. The Pearson correlation coefficient between the mean preference scores during ACQ and the number of chance pairings during PAV was then calculated.
In Experiment 2, active and inactive responses under the PR schedule were first analyzed using a three-way ANOVA with factors for sex, manipulandum, and session. Because this analysis revealed significant differences in active responding, but not inactive responding, the following aspects of PR performance were then each analyzed using a two-way ANOVA with factors for session and sex: reinforcers (i.e. the number of ratios completed), break point (i.e. the value of the final ratio completed), and total session duration (min). For all endpoints, following nonsignificant effects involving session, pairwise comparisons of the mean values were made post hoc using Bonferroni tests to compare active with inactive responding and/or males with females. To determine whether males and females differed in ACQ1, before the start of testing under the PR schedule, responding was analyzed using a two-way ANOVA, with factors for sex and manipulandum.
All analyses were carried out with Prism 6.0 (GraphPad Software, La Jolla, California, USA) or SPSS Statistics 21 (IBM, Armonk, New York, USA). All data are presented as the mean SEM. Differences were considered significant at P less than 0.05, two-tailed.
Results
Experiment 1: effects of remifentanil dose on the conditioned reinforcing effects of a remifentanil-paired stimulus Figure 1 presents rats' preference for the active nose-poke response after five sessions of paired PAV conducted with different doses of remifentanil. Figure 1a presents separately each of the seven ACQ sessions. During ACQ, preference for the active response in both males and females was significantly affected by the dose of remifentanil with which the stimulus had been paired [main effect of dose: F(4,106) = 13.48, P < 0.001; dose × sex: F(4,106) = 1.32, NS]. Preference did not significantly change across sessions (main effect of session and all interactions: 0.46 < F < 1.97, P's > 0.05). Therefore, the data were collapsed across sessions for pairwise comparisons (Fig. 1b) : males acquired responding for the stimulus after it was paired with 3.2 μg/kg [t(11) = 5.37, P < 0.001] or 10.0 μg/kg [t(9) = 6.47, P < 0.001] remifentanil, whereas females acquired responding for the stimulus after it was paired with 3.2 μg/kg [t(11) = 3.51, P < 0.025], 10.0 μg/kg [t(11) = 50.05, P < 0.002], or 32.0 μg/kg [t(11) = 4.19, P ≤ 0.01] remifentanil. All other preference scores were not different from zero (0.21 < t < 2.70, P's > 0.10). The main effect of sex only approached significance [F(1,106) = 3.73, P = 0.056]; however, pairwise comparisons were performed, given the difference between males and females in the range of doses that produced successful acquisition observed above. Numerically, females had greater preferences than males for the active response after receiving all nonzero doses of remifentanil; however, females had a significantly larger preference for the active response after paired PAV only with 32.0 μg/kg [t(20) = 2.92,
Figure 2a presents animals' preference for the active nose-poke after five sessions of random PAV conducted with the remifentanil doses that produced successful acquisition of responding after paired PAV. After random PAV, animals' preference for the active response varied across sessions [main effect of session: F(6,324) = 4.27, P < 0.001]; however, no effects of dose or sex were significant (main effects and all interactions: 0.24 < F < 2.60, P's > 0.05). Averaged across sessions (Fig. 2b) , neither males [2.07 < t(9) < 2.27, P's > 0.10] nor females [0.01 < t-(9) < 2.48, P's > 0.10] acquired responding after random PAV with any remifentanil dose. Figure 3a presents the animals' responding in each ACQ session. In ACQ1, under the RR2 schedule, responding did not differ by sex (main effect and sex × manipulandum: 2.08 < F < 2.14, P's > 0.05). Under the PR schedule, active and inactive responding differed significantly [main effect of manipulandum: F(1,20) = 25.62, P < 0.001]. Responding varied across sessions [main effect of session: F(5,110) = 2.60, P < 0.05]; however, this difference did not depend on either the manipulandum or the animals' sex (all interactions: 0.63 < F < 1.03, P's > 0.10). Averaged across sessions (Fig. 3b) , preference scores averaged across ACQ sessions: shaded symbol, P < 0.05, preference score significantly greater than zero, as assed using a Bonferroni-corrected one-sample t-test. *P < 0.05, significant difference within dose between males and females, as assessed by Bonferroni-corrected independent-samples t-test. ACQ, instrumental acquisition; PAV, Pavlovian conditioning. (Fig. 3c-d) , females had significantly longer sessions than males [main effect of sex: F(1,22) = 5.84, P < 0.025; t(22) = 2.41, P < 0.025], and there was a trend for females to have higher break points than males [main effect of sex: F(1,22) = 3.78, P = 0.064; t(22) = 1.94, P = 0.064]. All other differences were not significant.
Experiment 3: speed of establishing the stimulus as a conditioned reinforcer in males and females Figure 4 presents rats' preference for the active nosepoke response after one session of paired PAV with 10.0 μg/kg remifentanil. Preference did not differ significantly by sex or across sessions (both main effects and the interaction: 0.13 < F < 0.30, P's > 0.05). Averaged across sessions (Fig. 4a) , males significantly preferred the active response [t(9) = 4.04, P < 0.005], whereas females did not [t(11) = 1.77, NS]. As shown by the plot of the individual animals in Fig. 4a , this difference in the presence versus absence of acquisition depended on the greater variability of females' preference, rather than females having a smaller mean preference [t(20) = 0.18, NS]. Numerically, females had both the largest positive and largest negative preference scores.
Because males acquired responding after paired PAV, a random PAV control group of males was tested (Fig. 4b) . After one session of random PAV with 10.0 μg/kg remifentanil, males' responding did not differ across sessions [F(6,54) = 0.57, NS]. Averaged across sessions, males did not prefer the active response after random PAV [t(9) = 2.06, NS]. As shown in Fig. 4b , there was considerable variability in the animals' preference scores after random PAV, with two animals (#2, #4) showing a larger numerical preference for the active response than the others. To determine whether the chance pairing of remifentanil and the stimulus in the random PAV session could account for these differences, the number of pairings that animals experienced during the random PAV session (range: 2-9) was correlated with their mean preference during ACQ (data not shown). The association between chance pairings and preference for the active response was not significant (r = − 0.35, NS).
Discussion
Separate streams of research have made considerable progress in recent years in clarifying the importance of: (i) understanding the specific psychological processes that allow drug cues to control behavior (e.g. Berridge and Robinson, 2003; Milton and Everitt, 2010) and (ii) sex/ gender differences in drug abuse behaviors (e.g. Becker and Hu, 2008; Carroll and Anker, 2010) . However, work is still needed to bring these ideas together, to characterize the particular effects of sex/gender on the different behavioral mechanisms acting in drug abuse and dependence. To this end, the present study used newresponse acquisition to directly compare opioidconditioned reinforcement in male and female rats.
The remifentanil-paired stimulus dose-dependently served as a conditioned reinforcer in both males and females. During ACQ, both males and females made significantly more active responses than inactive responses after paired PAV, but not after random PAV. The animals' behavior was, thus, determined by both the particular consequences of the nose-pokes during ACQ and the contingency between remifentanil and the stimulus during PAV, as required for conditioned reinforcement (Mackintosh, 1974) . Having established that the stimulus was a conditioned reinforcer, we identified several differences between males and females.
In the dose-effect analysis, the stimulus was found to be reinforcing for females after it was paired with a broader range of remifentanil doses. In particular, females, but not males, acquired responding for the stimulus after it was paired with the highest dose of remifentanil tested, 32.0 μg/kg. This dose also comprised the descending limb of the dose-response function in both sexes. Previous studies on morphine or oxycodone in rats have produced results consistent with monotonic increases in opioid-conditioned reinforcement with increasing drug dose (Crowder et al., 1972; Grella et al., 2011) . However, these studies did not include the control conditions necessary to attribute the changes in responding to conditioned reinforcement, as opposed to other associative and nonassociative processes that can change responding, and, thus, dose-response effects are difficult to interpret. The present results are consistent with a dose-response study of morphine-conditioned place preference in rats (Cicero et al., 2000) : females, but not males, significantly preferred the morphine-paired chamber after it was paired with higher doses of morphine, and this behavioral difference was not associated with sex differences in brain levels of morphine.
The differences in ACQ observed presently are also unlikely to depend entirely on sex differences in remifentanil metabolism during PAV -that is, males and females experiencing vastly different remifentanil blood/ brain levels being paired with stimulus presentation given the same unit doses of remifentanil from the syringe drivers. First, a general sex difference in remifentanil metabolism would be expected to affect the animals' responses to both lower and higher doses, not the highest dose alone. Second, sex/gender differences in pharmacokinetics have been observed for other opioids that are metabolized hepatically, although these differences are ## P < 0.01, preference score significantly greater than zero, as assessed using a Bonferroni-corrected one-sample t-test. ACQ, instrumental acquisition; PAV, Pavlovian conditioning.
Opioid-conditioned reinforcement in the rat Bertz et al. 143 not observed consistently and are not consistently related to behavioral differences (Fillingim and Gear, 2004) . Remifentanil is, in contrast, metabolized by nonspecific tissue esterases, independently of hepatic and renal function (Servin and Billard, 2008) , and sex/gender differences in remifentanil metabolism have not been reported in clinical studies (Westmoreland et al., 1993; Minto et al., 1997) .
Considering opioid pharmacodynamics, although sex differences in opioid receptor density and function in rats have been reported (reviewed by Craft, 2008) , the associative complexity of conditioned reinforcement makes it difficult to interpret sex/gender differences strictly in terms of basic receptor properties (cf. Palmatier et al., 2008) . By definition, drug-conditioned reinforcement depends not only on the initial formation of an interoceptive stimulus (i.e. as drug molecules commence signaling cascades), but also on Pavlovian and instrumental learning operations performed on that stimulus. For instance, male and female rats may differ in the molecular mechanisms of opioid transduction (Selley et al., 2003) , but the behavioral differences observed may depend on sex differences in associative learning processes that involve other neurotransmitter systems (e.g. dopaminergic influences on Pavlovian incentive learning; Dickinson et al., 2000) . Despite these complexities, the dose-effect functions obtained presently show that drugconditioned reinforcement is amenable to foundational pharmacological analyses. More generally, new-response acquisition procedures should provide a valid behavioral basis for the work necessary to resolve further the neurobiological substrates of drug-conditioned reinforcement (see also Bertz et al., 2015) .
At a behavioral level, at least three types of effects could account for decreased responding when the stimulus was paired with a high dose of remifentanil, producing a descending limb in the dose-effect function: (i) high doses of remifentanil have aversive effects, resulting in a negative or inhibitory Pavlovian association; (ii) remifentanil has effects of memory/consciousness that prevent or disrupt association of the stimulus with remifentanil during PAV; (iii) as a Pavlovian conditioned stimulus (CS), the stimulus elicits conditioned responses (CRs) that are incompatible with nose-poke responding. Previous studies have shown that 32.0 μg/kg remifentanil maintains self-administration responding in male rats, and the interinjection intervals experienced by the animals in these studies are similar to the interinjection intervals used presently for PAV (i.e. up to ∼ 7 min; Panlilio and Schindler, 2000; Panlilio et al., 2003) . There can be significant differences between self-administered and experimenter-administered remifentanil (Crespo et al., 2005) , but it is unlikely that this high remifentanil dose is only aversive or is unable to enter into learned associations. Response-independent drug injections were used presently to avoid sex differences in opioid selfadministration behavior (reviewed above) that could affect subsequent responding for the stimulus alone, complicating analyses of conditioned reinforcement.
With regard to competing responses, it is important generally to recognize that any pairing of a stimulus with a primary reinforcer to create a conditioned reinforcer also renders that stimulus a Pavlovian CS that is capable of eliciting a variety of different CRs. These CRs may or may not be compatible with instrumental responding (Mackintosh, 1974; Cunningham, 1993; Williams, 1994) . Significant sex differences in rats have been observed in the unconditioned locomotor effects and the ratesuppressant effects of opioids in operant-conditioning experiments (reviewed by Craft, 2008) . The difference in the descending limb of the remifentanil-conditioned reinforcement dose-effect function may reflect a sex difference in the animals' susceptibility to conditioned locomotor effects caused by CS presentation. It is, however, crucial to re-emphasize that neither conditioned nor unconditioned locomotor activation alone can account for the acquisition of responding during ACQ. These possibilities are excluded by the significant differences between the nose-pokes observed on the basis of their consequences, as well as the different patterns of responding obtained after paired versus random PAV. Rather, these multiple effects/functions of cues that interact to determine performance with drug-conditioned reinforcement are analogous to the multiple effects/ functions of drugs themselves (e.g. primary reinforcing effects vs. 'direct' effects on behavior) that interact to determine performance with drug self-administration.
Under the PR schedule, females showed enhanced active, but not inactive, responding and worked for longer periods of time for the stimulus. In contrast to these results under the PR schedule, males and females did not differ when ACQ was assessed under the RR2 schedule after the stimulus was paired with 10.0 μg/kg remifentanil, considering either the preference scores presented in Fig. 1b or the raw data (i.e. active and inactive responses separately; data not shown). These differences in PR responding may indicate that the stimulus had greater relative reinforcing effectiveness for females than for males. This interpretation, including the lack of difference under a ratio schedule with a lower response requirement, is consistent with studies of drug self-administration under progressive versus fixed ratio schedules (see reviews by Arnold and Roberts, 1997; O'Brien and Gardner, 2005; Heidbreder, 2013) . However, we are hesitant to make this conclusion too forcefully, given the (small) size and (marginal to no) statistical reliability of the differences in break point and number of reinforcers earned. Further work is needed to understand how the relative effectiveness of drugconditioned reinforcers can best be established. Behavioral-economic demand curves have proven useful for characterizing the relative reinforcing effectiveness of primary drug reinforcers in drug self-administration studies (e.g. Koffarnus et al., 2012; Bentzley et al., 2013) . Demand curves may, likewise, aid in understanding the effectiveness or 'value' of conditioned reinforcers.
More generally, these differences obtained under the RR2 versus PR schedule highlight the importance of environmental factors in characterizing sex/gender differences in drug-related behaviors. Along with drug dose, schedule of reinforcement is one of the major determinants of the primary reinforcing effects of drugs, as assessed in self-administration experiments (e.g. Lagorio and Winger, 2014 ; see also reviews by Spealman and Goldberg, 1978; Arnold and Roberts, 1997; Moser et al., 2010) . Furthermore, schedule of reinforcement can change how pharmacological and neurological interventions affect drug self-administration behaviors (Bourland and French, 1995; Olmstead et al., 1998; Hutcheson et al., 2001; Heidbreder, 2013) , and schedule of reinforcement can interact with other environmental factors in selfadministration experiments (e.g. environmental enrichment; Green et al., 2002) . Therefore, it is reasonable that performance with drug-conditioned reinforcement is affected by schedule of reinforcement during ACQ, even when the same PAV parameters are used, and findings of this type are important in determining the breadth of circumstances under which sex/gender differences in drug abuse behaviors manifest (cf. Caine et al., 2004) .
Finally, in Experiment 3, the remifentanil-paired stimulus served as a conditioned reinforcer after only one session of PAV in males, but not females. Examining the individual animals ( Fig. 4a) , this difference depended on the relative consistency of preference for the active response among males, rather than a difference between males and females in the magnitude of preference. Comparing the effects of limited pairing with 10.0 μg/kg remifentanil in Experiment 3 with those of the extensive pairing used in Experiment 1, increasing the drug-stimulus pairing approximately tripled the magnitude of the preference scores for both sexes (Fig. 4a vs. Fig. 1b) , whereas increasing the number of random PAV sessions from one to five sessions produced a slight decrease in the males' mean preference score (8.1 vs. 7.9; Fig. 4b vs. Fig. 2b) . Along with the nonsignificant correlation with chance pairings in Experiment 3, this difference in the effect of increasing the amount of drug/ stimulus exposure indicates that the numerical preferences for the active response observed after random PAV are not due to drug-stimulus pairing, whereas the strength of the conditioned reinforcer does depend on the strength of the remifentanil-stimulus association (see also Bertz and Woods, 2013) .
Experiment 3 was designed to characterize a boundary condition (i.e. how little PAV could be used to create a conditioned reinforcer), and thus numerically small preferences and/or high variability are not unexpected. It is still noteworthy that a single episode with remifentanil is sufficient to establish a conditioned reinforcer in males. Nonetheless, it may be particularly important in future studies to address the source(s) of greater variability in females. As PAV was, in this case, confined to a single day, hormonal status may be a significant contributor. Little is currently known about the effects of gonadal hormones on the motivational effects of drug cues per se. In cocaine-trained animals, estrus cycle phase was found to have a small, but significant, effect on cue-primed reinstatement (Fuchs et al., 2005) . Studies assessing specifically the effects of gonadal hormones on opioidassociated stimuli are presently lacking, but estradiol has been shown to enhance heroin self-administration in ovariectomized females (Roth et al., 2002 ; but see Stewart et al., 1996 for negative results). The potential for significant hormonal effects is also supported by the ability of gonadal hormones to regulate the activity of a number of brain regions associated with the behavioral effects of drug-associated stimuli (Hudson and Stamp, 2011) .
Conclusion
Together, the present experiments provide, to our knowledge, the first demonstration of significant sex differences in a stringent test for drug-conditioned reinforcement. Rats' sex interacted in a complex manner with both pharmacological (drug dose, number of injections) and environmental (schedules of Pavlovian and instrumental reinforcement) variables to determine responding for the remifentanil-paired stimulus. Sex/gender differences have implications for both pharmacotherapies and behavioral interventions for treating drug abuse and dependence (e.g. Wetherington, 2010) , and thus the present results may be relevant to reducing the control over behavior exerted by opioid-associated stimuli in opioid-abusing men and women.
